Drug maker Trevi Therapeutics (TRVI) is climbing 4.5% after investment bank Stifel raised its price target on the name to $12 ...
Q4 2024 Management View CEO Olivier Loeillot highlighted that Repligen achieved Q4 2024 revenue of $167.5 million and full-year revenue of $634.4 million, meeting the midpoint of their November ...